Evolve Private Wealth LLC Invests $6.83 Million in United Therapeutics Corporation $UTHR

Evolve Private Wealth LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 14,020 shares of the biotechnology company’s stock, valued at approximately $6,831,000.

Other hedge funds also recently bought and sold shares of the company. Torren Management LLC bought a new stake in United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management grew its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new position in United Therapeutics in the 4th quarter worth approximately $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR opened at $551.47 on Thursday. The stock has a market capitalization of $23.41 billion, a price-to-earnings ratio of 20.36, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The business’s 50 day simple moving average is $565.95 and its 200-day simple moving average is $522.96.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the business posted $6.63 earnings per share. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,540,358.40. This represents a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 636,168 shares of company stock valued at $359,249,237. Company insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on UTHR shares. HC Wainwright upped their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Finally, Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.